Heralding a New Era of CNS-Targeted Oligonucleotides to the Clinic & Beyond
Uniting CNS Biotech & Pharma to Fuel the Next Wave of Oligonucleotide Drug Discovery, Translation & Clinical Progress
With clinical momentum from Eli Lilly’s lipidated brain shuttle siRNAs, Alnylam Pharmaceuticals’ ALN-APP siRNA, Wave’s Phase 1b/2a positive SELECT-HD data, 170+ biotech and 30+ pharma active in the field, and a surge of novel approaches, the oligonucleotide field shows no signs of slowing down.
The 5th Oligonucleotides for CNS Summit unites a select group of industry-leading biologists, chemists, C-level executives, platform tech experts, DMPK and clinical pharmacologists, all tackling the unique challenges of CNS delivered ASOs, siRNAs, miRNAs and saRNAs.
This August, hear from Alnylam Pharmaceuticals, Denali Therapeutics, Genentech, FDA, Novo Nordisk, Regeneron, Servier, Stoke Therapeutics, Ultragenyx Pharmaceutical and more, to redefine the landscape of oligonucleotide research.
Check Out the 2025 Agenda:
Unpublished insights and never-seen-before data
Two tracked workshop day designed for chemists and biologists
10 new presenting companies including Denali Therapeutics, Alnylam Pharmaceuticals and Novo Nordisk
Regulator presence from Ron Wange, a former FDA expert and author of the non-clinical guidance for oligonucleotides
Poster Session: Thursday, August 28 | 2.30- 3.30 pm
This session is free for all attendees and offers a fantastic opportunity to showcase and discuss the latest scientific research.
To participate, please complete the submission form by Wednesday, August 20th at the latest.
Further instructions will be provided upon approval.
*Please note posters should not be used for sales and marketing purposes, and vendor delegates will not be permitted to submit. All abstracts are subject to approval by the conference organisers.
World-Class Speaker Faculty:
Previously Attending Companies:
Hear from Your Peers:
"This summit brings together key stakeholders, including industry leaders, researchers, and regulatory experts, to collaboratively address challenges, share innovative solutions, and explore the transformative potential of oligonucleotide therapeutics in advancing treatment options for CNS disorders"
Nicole Lykens, Director of Neurobiology, Global Nucleic Acid Therapies (GNAT), Novo Nordisk
"CNS is the next frontier in ASO and RNA therapeutics. Attending this conference will provide me, and you, a front row seat to follow the latest achievements, current developments and future aspirations of companies and its stakeholders active in this exciting space"
Jimmy Weterings, Vice President, Head of Oligonucleotide Therapeutics, Bonito Biosciences
Proud to Partner With:
Other Events in the Series:
